Community-acquired Pneumonia Guideline Recommendations-Impact of a Consensus-based Process versus Systematic ReviewsCLINICAL INFECTIOUS DISEASESIF7.32020-09-226OAAI
Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 (Reprinted from MMWR RECOMMENDATIONS AND REPORTS, vol 69, 2020)AMERICAN JOURNAL OF TRANSPLANTATIONIF8.22020-04-0131OAAI
Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and ChildrenCLINICAL INFECTIOUS DISEASESIF7.32017-01-03680OAAI
Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and ChildrenCLINICAL INFECTIOUS DISEASESIF7.32016-12-08177OAAI
John A. Sbarbaro, 1936-2011 ObituaryINTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASEIF3.12011-11-010PREAI
Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected MenJOURNAL OF INFECTIOUS DISEASESIF4.52010-10-15185OAAI
An official ATS statement: Hepatotoxicity of antituberculosis therapyAMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINEIF19.42006-10-15874PREAI
Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: Is it different than in HIV-uninfected persons?CLINICAL INFECTIOUS DISEASESIF7.32004-08-1559OAAI
When to begin highly active antiretroviral therapy?: Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/μLCLINICAL INFECTIOUS DISEASESIF7.32003-10-0137PREAI
Fatal liver injury associated with rifampin-pyrazinamide treatment of latent tuberculosis infectionCHESTIF8.62003-03-019PREAI
The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trialAIDSIF3.12001-09-01102OAAI
Tolerance and pharmacokinetic interactions of rifabutin and azithromycinANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52001-05-0120OAAI
A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: Differences in study outcomesCLINICAL INFECTIOUS DISEASESIF7.32001-02-1576OAAI
Breaking the camel's back: Multicenter clinical trials and local institutional review boardsANNALS OF INTERNAL MEDICINEIF15.22001-01-16128PREAI
Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS:: A randomized, double-blind, placebo-controlled trialJOURNAL OF INFECTIOUS DISEASESIF4.52000-04-0168OAAI
A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients:: Excess mortality associated with high-dose clarithromycinCLINICAL INFECTIOUS DISEASESIF7.31999-07-0150OAAI
A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complexCLINICAL INFECTIOUS DISEASESIF7.31999-05-01101OAAI
Comparison of health status, socioeconomic characteristics, and knowledge and use of HIV-related resources between HIV-infected women and menMEDICAL CAREIF2.81998-12-0126PRE
Long-term outcomes of treatment of Mycobacterium avium complex bacteremia using a clarithromycin-containing regimenAIDSIF3.11998-07-0112OAAI